CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) indication: atopic dermatitis
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2020, April 24, 2020
|
| Edition: | Final |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Item Description: | "This recommendation supersedes the CADTH Canadian Drug Expert Committee recommendation for this drug and indication dated June 27, 2018." |
|---|---|
| Physical Description: | 1 PDF file (10 pages) |